Homology Medicines Inc. (NASDAQ:FIXX) changes shares on Wednesday trading session, with a change of -4.82% or -$0.66 shares. The trading starts at $13.77 and closed at $13.70 throughout the day. The trading session low price was $12.82 and day high was $13.9896 on Wednesday, August 05. After the session, the Healthcare sector daily volume shifted to 0.59 million while its average volume is 509.55K. In other hand, the FIXX market cap reached to $625.01M.
On March 16, 2020, BRIEF-Homology Medicines Announces Peer-Reviewed Publication Of HMI-102 Investigational Gene Therapy. According to the news reported on Reuters, * HOMOLOGY MEDICINES ANNOUNCES PEER-REVIEWED PUBLICATION OF HMI-102 INVESTIGATIONAL GENE THERAPY DEMONSTRATING RESTORATION OF NORMAL METABOLIC PATHWAY IN PKU DISEASE MODEL
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -6.05% and down -21.40% for month. Its quarterly performance was 2.52% above, while its half year performance is down -27.27%. FIXX yearly performance stood at negative -18.40% and fall -37.00% for year-to-date. Current recommendation for Homology Medicines Inc. is 1.50.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. FIXX EPS (TTM) for 12-month is -2.62. EPS for this year is -26.80%, while for the next year its value is -2.86. Its EPS Q/Q reached -22.60%. It has an EPS of next five years will be down -9.40%.
5AM Venture Management, LLC, RTW Investments LP and Deerfield Management Company, L.P. (Series C) are the top three holders in Homology Medicines Inc. (FIXX) stock. On Mar 30, 2020, 5AM Venture Management, LLC has 5.54 million shares which valued 86.03 million. On Mar 30, 2020, RTW Investments LP owned 4.4 million shares which valued at 68.36 million. On Mar 30, 2020, Deerfield Management Company, L.P. (Series C) has a total of 4.04 million shares which valued at 62.74 million. In the end, Deerfield Management Company, L.P. (Series C) have 8.93% shares outstanding of Homology Medicines Inc. (FIXX) on Mar 30, 2020. The insider ownership moved to 0.20% and institutional holding shifted to 91.70%.
The company posted an EPS (TTM) of -2.62. According to the most recent quarter report on (Jun 2020), 9 analysts estimated an average EPS of -0.76, while -0.61 EPS posted a year ago period. Analyst Estimated EPS for FIXX published in the report was -$0.85 – -$0.59 during the same period. Comparing with last year, the average estimated EPS was -0.61 which is higher than -0.78 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for FIXX fall -17.72% for period of 200 days. SMA for 50 days was -14.52% which is showing red signal, while SMA-20 was -12.06%. The moving average value for Homology Medicines Inc. (FIXX) is 15.55 and 15.15 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in FIXX stock. On Mar 17, Kelly Timothy P, See Remarks, sold 1,315 trading shares at the cost of $13.01, which valued at 17109.0. On Feb 03, Smith W Bradford, CFO, Treasurer & Secretary, sold 12,000 shares at the cost of $16.16, with total shares of 0. On Feb 03, TZIANABOS ARTHUR, President & CEO, sold 12,500 shares at the cost of 16.16. After this transaction, TZIANABOS ARTHUR total shares reached to 77,505 which valued at 0.2 million.